title: [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
abstract: Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses). Complete suppression rate of nausea or vomiting were approximately 75%, approximately 90% respectively for every treatment day. According to judgement criteria, antiemetic rate of approximately 100% was achieved during the study period. As to food intake of each treatment day, in approximately 70% of treatment courses was assessed as '(patient was) able to eat most of the meal'. Trend in emetic episodes and food intake in each patient receiving several courses of CAF therapy were evaluated. As a result, those patients experiencing nausea or vomiting or had effect on their food intake, were found to be in the similar condition in the following course (s) of CAF. No adverse drug reaction nor clinical laboratory test abnormalities due to ondansetron was observed. In this investigation, combination of ondansetron injection and tablet was shown to sufficiently suppress CAF-induced nausea and vomiting, and their efficacy was confirmed. Still, the study suggested that number of emetic episodes or degree of anorexia differs according to each individual. Therefore we regard additional administration of ondansetron or concomitant use of steroids should be considered when necessary.
authors.affiliation: Dept. of Surgery, National Ohkura Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Shinohara
authors.forename: H
authors.initials: H
authors.lastname: Yonekawa
authors.forename: T
authors.initials: T
authors.lastname: Machimura
authors.forename: T
authors.initials: T
authors.lastname: Furukawa
authors.forename: H
authors.initials: H
authors.lastname: Nishihori
authors.forename: N
authors.initials: N
authors.lastname: Kurihara
authors.forename: H
authors.initials: H
authors.lastname: Urakami
authors.forename: Y
authors.initials: Y
authors.lastname: Nemoto
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D017294:Ondansetron / Q000008:administration & dosage*; D013607:Tablets; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D013607:Tablets; D017294:Ondansetron; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil